Longitudinal and continuous label-free monitoring of glioblastoma patient-derived tumor spheroid treatment response using quantitative oblique back illumination microscopy
Authors:
- Caroline SerafiniCSCaroline Serafini
- Amin DavarzaniADAmin Davarzani
- Dan CappabiancaDCDan Cappabianca
- Zhenmin LiZLZhenmin Li
- Daniela Baez CollazosDCDaniela Baez Collazos
- Deniz MamaghaniDMDeniz Mamaghani
- Leidong MaoLMLeidong Mao
- Krishanu SahaKSKrishanu Saha
- Lohitash KarumbaiahLKLohitash Karumbaiah
- Francisco RoblesFRFrancisco Robles
Preprint
- 30 April 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and poor patient survival, underscoring the need for novel therapeutic strategies and improved preclinical models. Patient-derived tumor spheroids (PDTSs) offer a physiologically relevant in vitro platform for evaluating treatments such as chimeric antigen receptor (CAR) T cell therapy, chemotherapy, and radiation. However, significant challenges remain in monitoring the complex three-dimensional (3D) microenvironment of the GBM PDTSs. Current imaging techniques used for this purpose are primarily endpoint analyses which lack critical real-time, non-invasive capabilities that ultimately preclude longitudinal and continuous monitoring. In this study, we introduce quantitative Oblique Back-illumination Microscopy (qOBM) as a novel, label-free, and non-invasive imaging approach for longitudinal and continuous, high-resolution monitoring of GBM PDTSs during treatment. qOBM enables real-time visualization of cellular processes, including apoptosis, cell migration, and T cell-mediated cytotoxicity by leveraging tomographic refractive index-based quantitative imaging. We construct a compact qOBM system that fits within common incubators and apply it to study the effects of radiation, chemotherapy, and immunotherapy on three patient-derived GBM cell lines, extracting both static and dynamic image features over a 72-hour treatment period. Additionally, we develop machine learning models to predict spheroid viability and cytotoxicity, demonstrating the potential of qOBM to enhance treatment evaluation. Our findings establish qOBM as a powerful tool for longitudinal and continuous spheroid monitoring, offering a non-destructive, high-resolution alternative to conventional endpoint assays and improving the evaluation of preclinical treatments for GBM.Keywords
All Related Versions
- Version 1, 2025-04-30, Research Square
- Published version: Optica, 13 (2), 211.
This publication has 57 references indexed in Scilit:
- In Vitro Assessment of Thermo‐Responsive Scaffold as a 3D Synthetic Matrix for CAR‐T Potency Testing Against Glioblastoma SpheroidsJournal of Biomedical Materials Research Part A, 2024
- A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral HeterogeneityCell, 2019
- Rectal Organoids Enable Personalized Treatment of Cystic FibrosisCell Reports, 2019
- Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder CancerCell, 2018
- Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal TransitionCell Reports, 2016
- A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agentsCancer Immunology, Immunotherapy, 2016
- Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV ExposureCell, 2016
- High-resolution deep imaging of live cellular spheroids with light-sheet-based fluorescence microscopyCell and tissue research, 2013
- Diffusion, Transport, and Cell Membrane Organization Investigated by Imaging Fluorescence Cross-Correlation SpectroscopyBiophysical Journal, 2009
- Polar Plot Representation for Frequency-Domain Analysis of Fluorescence LifetimesJournal of Fluorescence, 2005